Ligand Pharms Cvr Stock EBITDA
| LGNDZ Stock | USD 0 0.00 0.00% |
Ligand Pharms Cvr fundamentals help investors to digest information that contributes to Ligand Pharms' financial success or failures. It also enables traders to predict the movement of Ligand Pink Sheet. The fundamental analysis module provides a way to measure Ligand Pharms' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ligand Pharms pink sheet.
Ligand |
Ligand Pharms Cvr Company EBITDA Analysis
Ligand Pharms' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Ligand Pharms EBITDA | 98.42 M |
Most of Ligand Pharms' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ligand Pharms Cvr is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Ligand Pharms Cvr reported earnings before interest,tax, depreciation and amortization of 98.42 M. This is much higher than that of the Other sector and significantly higher than that of the Other industry. The ebitda for all United States stocks is notably lower than that of the firm.
Ligand EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ligand Pharms' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Ligand Pharms could also be used in its relative valuation, which is a method of valuing Ligand Pharms by comparing valuation metrics of similar companies.Ligand Pharms is currently under evaluation in ebitda category among its peers.
Ligand Fundamentals
| Revenue | 277.13 M | |||
| EBITDA | 98.42 M | |||
| Net Income | 57.14 M | |||
| Cash Flow From Operations | 78.8 M | |||
| Total Asset | 1.3 B | |||
| Net Asset | 1.3 B |
About Ligand Pharms Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ligand Pharms Cvr's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ligand Pharms using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ligand Pharms Cvr based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| WMT | Walmart | |
| MIDNX | Matthews India Fund | |
| QCOM | Qualcomm Incorporated |
Additional Tools for Ligand Pink Sheet Analysis
When running Ligand Pharms' price analysis, check to measure Ligand Pharms' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharms is operating at the current time. Most of Ligand Pharms' value examination focuses on studying past and present price action to predict the probability of Ligand Pharms' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharms' price. Additionally, you may evaluate how the addition of Ligand Pharms to your portfolios can decrease your overall portfolio volatility.